News
Quicker methods of thawing embryos can increase efficiency while maintaining pregnancy rates, shows research
Two lab studies have evaluated rapid warming protocols leading to a more efficient workflow with comparable pregnancy rates
New research from US Fertility has evaluated methods of thawing embryos, comparing standard protocols with an improved, more efficient method.
The two studies conducted by US Fertility physicians studied the outcomes of more efficient protocols and found that quicker methods of thawing embryos can increase efficiency without compromising ongoing pregnancy rates.
“Our team is dedicated to providing evidence-based, patient-centred fertility and family-building care,” said Juergen Liebermann, director of laboratories the Fertility Centers of Illinois.
“This study demonstrated that a faster warming protocol maintained excellent outcomes. Gaining efficiency in the embryology laboratory will allow us to expand access and help more patients achieve their dreams of growing their family.”
In one retrospective study, 833 frozen embryo transfers (FETs) using a one-step rapid warming protocol (RWP) were compared to 2,606 FETs using a standard two-step warming protocol.
The more efficient protocol produced similar survival rates post-thaw and comparable clinical pregnancy rates to the standard protocol and — perhaps more notably and worthy of further studies — the RWP saw increased rates of ongoing pregnancy and decreased rates of miscarriage.
In another retrospective cohort study across four IVF labs, 6,746 FETs warmed by traditional warming were compared to 6,838 FETs warmed by quick warming.
In this large dataset, the quick warming method produced similar results to the traditional warming method. This data may allow IVF labs to deliver even more superior, streamlined patient care.
Michael J. Tucker, scientific director of Shady Grove Fertility‘s IVF and embryology laboratories, said: “One of the driving factors of our research team is improving patient care.
“Our latest research will allow IVF labs to deliver superior patient care with increased efficiency through the use of quick warming protocols.”
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Wellness3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur7 days agoUS startup builds wearable hormone tracker
-
Menopause3 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Menopause2 weeks agoStudy reveals gap between perimenopause expectations and experience
-
Pregnancy6 days agoFrance urges 29-year-olds to start families now







1 Comment